New targeted drug shows promise for Hard-to-Treat bile duct cancers
Disease control
Completed
This study tested a new drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific changes in the FGFR2 gene. The drug is designed to block FGFR2, which can help stop cancer growth. The main goals were to find the best dose and see …
Phase: PHASE1, PHASE2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated May 06, 2026 16:01 UTC